bioRxiv Science⌕ Search

Biology subjects

Andruska, A. M.

Publications and source records attributed to Andruska, A. M..

3 recordsLinked to original sources

An embryonic artery-forming niche reactivates in pulmonary arterial hypertension

Developmental programs that orchestrate cell fate and tissue architecture during organogenesis can cause disease when reactivated in adults. Here we identify a population of endothelial cells (ECs) defined by the pioneer factor early B cell factor 1 (EBF1) that controls both pulmonary artery (PA) morphogenesis and pulmonary arterial hypertension (PAH). During embryonic development, the PA emerges from an endothelial niche harbored within the vascular plexus, where Aplnr+ endothelial progenitors give rise to both arterial ECs and EBF1+ ECs. Rather than directly incorporating into the PA intima, EBF1+ ECs control the branching and maturation of the PA tree through paracrine vasculotrophic signals that direct plexus expansion, arterialization, and mural cell recruitment. Although essential for development, most EBF1+ ECs disappear upon completion of PA morphogenesis. In adult PAH, vascular injury reactivates this developmental program: normally quiescent general capillary ECs re-enter the cell cycle and differentiate into arterial ECs and EBF1+ ECs, reconstituting this artery-forming niche in a maladaptive reprise. Unlike their transient embryonic counterparts, EBF1+ ECs persist within neointimal lesions and express vasculotrophic signals associated with pathological PA remodeling. Capillary-restricted Ebf1 induction combined with endothelial injury recapitulates this program, driving neo-arterialization, neointimal formation, and severe PAH. Conversely, endothelial-targeted AAV-mediated Ebf1 knockdown achieves complete protection in a preclinical model of disease, demonstrating that endothelial EBF1 is necessary for PAH pathogenesis. These findings demonstrate that reactivation and persistence of a transient embryonic artery-forming niche in adulthood can promote pathological vascular remodeling and PAH.

developmental biology↗

Rat microbial biogeography and age-dependent lactic acid bacteria in healthy lungs

The laboratory rat emerges as a useful tool for studying the interaction between the host and its microbiome. To advance principles relevant to the human microbiome, we systematically investigated and defined a multi-tissue full lifespan microbial biogeography for healthy Fischer 344 rats. Microbial community profiling data was extracted and integrated with host transcriptomic data from the Sequencing Quality Control (SEQC) consortium. Unsupervised machine learning, Spearmans correlation, taxonomic diversity, and abundance analyses were performed to determine and characterize the rat microbial biogeography and the identification of four inter-tissue microbial heterogeneity patterns (P1-P4). The 11 body habitats harbor a greater diversity of microbes than previously suspected. Lactic acid bacteria (LAB) abundances progressively declined in lungs from breastfeed newborn to adolescence/adult and was below detectable levels in elderly rats. LABs presence and levels in lungs were further evaluated by PCR in the two validation datasets. The lung, testes, thymus, kidney, adrenal, and muscle niches were found to have age-dependent alterations in microbial abundance. P1 is dominated by lung samples. P2 contains the largest sample size and is enriched for environmental species. Liver and muscle samples were mostly classified into P3. Archaea species were exclusively enriched in P4. The 357 pattern-specific microbial signatures were positively correlated with host genes in cell migration and proliferation (P1), DNA damage repair and synaptic transmissions (P2), as well as DNA transcription and cell cycle in P3. Our study established a link between metabolic properties of LAB with lung microbiota maturation and development. Breastfeeding and environmental exposure influence microbiome composition and host health and longevity. The inferred rat microbial biogeography and pattern-specific microbial signatures would be useful for microbiome therapeutic approaches to human health and good quality of life. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/541527v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@1387224org.highwire.dtl.DTLVardef@cdb7dborg.highwire.dtl.DTLVardef@1e1c7ccorg.highwire.dtl.DTLVardef@440ca_HPS_FORMAT_FIGEXP M_FIG C_FIG

microbiology↗

Selective Src-Family B Kinases Inhibition Promotes Pulmonary Artery Endothelial Cell Dysfunction.

Protein tyrosine kinase (PTK) inhibition is efficacious in treating conditions ranging from cancer to fibrosis but can be limited by endothelial cell dysfunction. In trials of protein tyrosine kinase inhibitors (TKIs) a broad range of vascular effects is observed, inducing clinically detrimental endothelial cell apoptosis, impaired barrier function, or improved pulmonary vascular resistance in pulmonary arterial hypertension (PAH). We hypothesize this range of effects is due to subsets of PTKs either impairing or promoting endothelial homeostasis by modulating Bone Morphogenetic Protein receptor 2 (BMPR2) signaling, a pathway essential for vascular development and dysfunctional in PAH. In a high-throughput siRNA screen we find SRC-Family B PTKs activate whereas SRC-Family A PTKs suppress BMPR2 signaling, measured by the transcription factor inhibitor of differentiation 1 (Id1). Induced loss of function of the strongest ID1 activating PTK LCK (a Src-B kinase) in human pulmonary artery endothelial cells suppresses BMPR2 signaling and induces multiple measures of endothelial dysfunction. However, loss of function of the strongest ID1 inhibitor PTK FYN (a Src- A kinase) does the opposite. Whole-genome transcriptional analysis identifies two multi-gene signatures inversely regulated by LCK and FYN we term "endothelial" and "inflammatory". To find TKIs mimicking selective Src-A and Src-B inhibition, we use Connectivity map to identify drugs connecting to the endothelial and inflammatory signatures. We find several TKIs: a pro-inflammatory (Regorafanib), a BMPR2 potentiating (Brivanib), and a BMPR2 suppressing (Quizartinib). Here we show a dichotomy in pathway regulation by Src- A and -B kinases that may have utility in transcriptionally based drug discovery.

molecular biology↗